Stock BGNE BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
153.1 USD +0.26% Intraday chart for BeiGene, Ltd. -8.53% -15.11%
May. 28 BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study MT
May. 28 BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments
MT
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
AQ
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study
CI
BeiGene Says Studies Highlight Effectiveness, Safety of Lymphoma Drug Brukinsa
MT
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
BU
BeiGene, Ltd. Announces New Analyses for BRUKINSA® (zanubrutinib) At ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
CI
Glenmark Pharma Arm to Market Two Beigene Cancer Drugs in India
MT
Glenmark Specialty S.A. Announces an Exclusive Marketing and Distribution Agreement with BeiGene
CI
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
BU
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
CI
Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday
MT
BeiGene's Q1 Loss Narrows as Revenue Rises
MT
Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $752M
MT
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
BU
BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
BeiGene, Ltd. Anticipates Opening of Biologics Manufacturing Facility and Clinical R&D Center at the Princeton West Innovation Campus in Hopewell, New Jersey, in July 2024
CI
Amgen Posts Higher 1Q Revenue, Swings to Loss
DJ
BeiGene : Financial Information - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.